HPSE and cancer: Heparin/HS-mimetics (i.e., Muparfostat = PI-88, Roneparstat = SST0001, Necuparanib = M402, Pixatimod = PG545) that inhibit heparanase enzymatic activity were and are being evaluated in clinical trials for various types of cancer and appear to be well tolerated [18,19,20,21].